Boceprevir and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Boceprevir
No brand names on recordCariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Boceprevir is a strong blocker of a liver enzyme called CYP3A4, which is the same enzyme your body uses to clear cariprazine (Vraylar). When boceprevir slows that enzyme down, cariprazine and its long-lasting active form can build up higher than usual. That could mean more side effects, like restlessness, drowsiness, muscle stiffness, or movement changes.
The good news is that this is very manageable. Your care team can simply use a lower or less frequent cariprazine dose while you're on boceprevir. Please don't change anything on your own. Just let your pharmacist or doctor know you're taking both so they can tailor your dose and watch how you're feeling.
Mechanism: Cariprazine is a CYP3A4 substrate; boceprevir is a strong CYP3A4 inhibitor. Inhibition reduces clearance of cariprazine and its active metabolite didesmethylcariprazine, increasing exposure (AUC/Cmax). Neither agent is a prodrug requiring activation here.
Evidence: Theoretical. Severity: major. Onset: unspecified.
Management (per labeling with a strong 3A4 inhibitor):
- Schizophrenia/bipolar mania initiation: 1.5 mg every 3 days, may increase to 1.5 mg every other day per response/tolerability.
- Bipolar depression/MDD adjunct: 1.5 mg every 3 days.
- Stable 1.5 or 3 mg daily: reduce to 1.5 mg every 3 days.
- Stable 4.5 or 6 mg daily: reduce to 1.5 mg every other day.
On inhibitor discontinuation, cariprazine dose may need increasing. Coadministration with CYP3A4 inducers is not recommended.
What happens
Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine
Interaction Deep Dive
Giving cariprazine (a substrate of CYP3A4) together with a potent CYP3A4 inhibitor can raise the exposure of cariprazine as well as its active metabolite, didesmethylcariprazine. If cariprazine is being started in a patient already receiving a strong CYP3A4 inhibitor (for schizophrenia or bipolar mania), begin dosing at 1.5 mg by mouth every 3 days; this can be raised to 1.5 mg orally every other day when necessary, guided by the patient's clinical response and tolerability. For someone taking a strong CYP3A4 inhibitor who is being treated for bipolar depression or receiving cariprazine as adjunctive therapy for major depressive disorder (MDD), give 1.5 mg orally every 3 days. In the situation where a strong CYP3A4 inhibitor is being added to an established cariprazine regimen: for patients currently taking 1.5 or 3 mg once daily, modify the cariprazine dose to 1.5 mg orally every 3 days upon starting the inhibitor. For patients currently on 4.5 or 6 mg once daily, change the cariprazine dose to 1.5 mg orally every other day when the inhibitor is begun. Should the strong CYP3A4 inhibitor be stopped, an increase in the cariprazine dose may be warranted according to clinical response and tolerability. Furthermore, using cariprazine (a CYP3A4 substrate) alongside a CYP3A4 inducer is not advised. CYP3A4 handles both the formation and the elimination of cariprazine's active metabolites. Because the impact of CYP3A4 inducers on cariprazine exposure has not been studied, the overall effect remains uncertain1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediate cariprazine metabolism; induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Keep taking both medications as prescribed and let your care team know you're on them together. Because boceprevir raises cariprazine levels, your team will likely use a lower, less frequent cariprazine dose while you're on boceprevir, and adjust it based on how you respond and tolerate it.
- Your cariprazine dose may be reduced (for example, taken every 3 days or every other day) rather than once daily.
- Your team may monitor you more closely for side effects such as restlessness, drowsiness, or muscle stiffness.
- When boceprevir is stopped, your cariprazine dose may need to be raised again.
Ask your pharmacist or prescriber before making any change yourself.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 0.5 mg/day together with ketoconazole (a strong CYP3A4 inhibitor) 400 mg/day led to an increase in total cariprazine AUC and Cmax of about 100% 1.
Common questions
Can I take Boceprevir and Cariprazine together?
Boceprevir can raise cariprazine (Vraylar) levels by blocking the enzyme that clears it, so your doctor will likely lower or space out your cariprazine dose while watching for side effects. Don't change anything on your own; check with your pharmacist or prescriber. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Boceprevir and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Boceprevir and Cariprazine interaction managed?
Keep taking both medications as prescribed and let your care team know you're on them together. Because boceprevir raises cariprazine levels, your team will likely use a lower, less frequent cariprazine dose while you're on boceprevir, and adjust it based on how you respond and tolerate it. Your cariprazine dose may be reduced (for example, taken every 3 days or every other day) rather than once d… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Boceprevir or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Boceprevir
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist